Answer

When should you start HRT - and can you start in perimenopause?

HRT & Menopause hrt perimenopause menopause timing

Verdict

Leaning for

HRT gives the most benefit when started near menopause onset, within about 10 years.

+9 25 sources: 12 positive, 12 partly, 1 negative

25 sources: 12 positive, 12 partly, 1 negative

By Arun AgrahriLast reviewed

Based on what researchers say in public interviews on YouTube. Educational only, not medical advice. Ask a qualified clinician before changing a supplement, medication, treatment, or testing plan.

Short answer

Near menopause onset, broadly within about 10 years, at ages ~50-59, which is where the bone, heart and brain benefits concentrate. You do not have to wait for periods to stop; starting when perimenopausal symptoms begin is on the record too. The FDA's Nov 2025 label update echoes that window. Timing and candidacy are physician decisions.

Leaning for

Hormone therapy around menopause does more good than harm for most women.

The verdict on HRT & Menopause overall. 12 sources: 4 positive, 8 partly

What the evidence says

positive partly neutral negative Each researcher and each study counts once per claim, however often they come up.

  1. Leaning for

    HRT gives the most benefit when started near menopause onset, within about 10 years.

    25 sources: 12 positive, 12 partly, 1 negative.

    Researchers say

    2 partly

    Studies show

    12 positive, 10 partly, 1 negative

    18 papers we read · 5 cited on tape, not yet checked against the paper

    66 more not counted · see why
    The study is not yet read in full. 32
    We could not confirm who is speaking. 9
    The study cited could not be identified. 9
    We could not tell what position it takes on this claim. 8
    We could not tell where the evidence comes from. 4
    A host's remark inside an interview. 3
    The same study is already counted once. 1
    Show the receipts from 25 sources

    1. KEEPS and ELITE, cited on The Dr. Hyman Show, at 45:18 Study · positive

      “introducing hormones within the fiveyear window of the last menstrual period 5 to 10 year window of the last menstrual period in most women”

    2. Other primary study, J Neurol Neurosurg Psychiatry, 2005, PMID 15608005 Study · positive

      In stratified analyses, a significant protective association was seen only in the youngest age tertile (50-63 years; odds ratio = 0.35, 95% confidence interval = 0.19 to 0.66).

    3. Other primary study, J Womens Health (Larchmt), 2006, PMID 16417416 Study · positive

      Women beginning HT near menopause had a significantly reduced risk of CHD (RR = 0.66, 95% CI 0.54-0.80 for estrogen alone; RR = 0.72, 95% CI 0.56-0.92 for estrogen with progestin).

    4. Other primary study, Neurology, 2009, PMID 19470968 Study · positive

      Hormone initiation prior to the final menstrual period had a beneficial effect whereas initiation after the final menstrual period had a detrimental effect on cognitive performance.

    5. Other primary study, Climacteric, 2010, PMID 20540591 Study · positive

      Recent findings in the limited numbers of younger menopausal women in the WHI CEE + MPA trial, and findings in the CEE-only trial, suggest that age at initiating HT strongly influences outcomes, and that benefits greatly exceed risk for most women who start within 10 years of menopause.

    6. Trial or observed group, Ann Neurol, 2011, PMID 21280086 Study · positive

      Compared to women never on HT, those taking HT only at midlife had a 26% decreased risk (multivariate adjusted hazards ratio [aHR], 0.74; 95% confidence interval [CI], 0.58-0.94 ), whereas those taking HT only in late life had a 48% increased risk (aHR, 1.48; 95% CI, 1.10-1.98), and women taking HT at both mid and late life had a similar risk of dementia (aHR, 1.02; 95% CI, 0.78-1.34 ).

    7. Other primary study, Climacteric, 2012, PMID 22612607 Study · positive

      Cumulated data support a 'window-of-opportunity' for maximal reduction of CHD and overall mortality and minimization of risks with HRT initiation before 60 years of age and/or within 10 years of menopause and continued for 6 years or more.

    8. Other primary study, Neurology, 2012, PMID 23100399 Study · positive

      Women who used any type of HT within 5 years of menopause had 30% less risk of AD (95% confidence interval 0.49-0.99), especially if use was for 10 or more years.

    9. Trial or observed group, Metabolism, 2016, PMID 27085786 Study · positive

      However, a nuanced look at the data from this trial, considered alongside other evidence, suggests that timing of HT initiation affects the relation between such therapy and coronary risk, as well as its overall benefit-risk balance.

    10. Other primary study, J Clin Endocrinol Metab, 2016, PMID 27172432 Study · positive

      Estradiol-based hormone therapies are accompanied with larger CHD mortality risk reductions the earlier the therapies are initiated.

    11. Other primary study, Menopause, 2019, PMID 31613825 Study · positive

      The timing of HT initiation was significantly associated with 3MS (β = 0.55, P = 0.048), with higher scores for women who initiated HT within 5 years of menopause compared with those initiating HT 6-or-more years later.

    12. Other primary study, Cancer J, 2022, PMID 35594469 Study · positive

      Initiated in women at younger than 60 years and/or at or near menopause, HRT significantly reduces all-cause mortality and cardiovascular disease (CVD), whereas other primary CVD prevention therapies such as lipid-lowering fail to do so.

    13. Joanne Manson Video · partly · 2 mentions

      on The Drive, at 55:40 · partly · Opinion

      “the best candidates are women in early menopause who have moderate to severe or bothersome hot flashes and night sweats”

      on The Drive, at 1:15:06 · partly · Opinion

      “in her specific case in early menopause and generally good health the benefits are likely to outweigh the risk”

    14. Peter Attia, on The Drive, at 10:43 Video · partly · Opinion

      “we want to do it as she's transitioning from this into that”

    15. American Heart Association 2020, cited on Huberman Lab, at 1:13:49 Study · partly

      “started hormone therapy between the ages of 50 to 59 you had a 50% decreased risk of cardiovascular disease”

    16. Women's Health Initiative, cited on The Dr. Hyman Show, at 54:55 Study · partly

      “to get the maximum benefit, the earlier you start in this process, the more long-term benefit you're going to get.”

    17. Levy and Simon, Obstetrics and Gynecology 2024, cited on The Dr. Hyman Show, at 28:53 Study · partly

      “we have a window of opportunity for protection for cardiovascular disease”

    18. Other primary study, Ann N Y Acad Sci, 2005, PMID 16024750 Study · partly

      Given the uncertain relevance of the WHI (and other published randomized clinical trials) to initiation of HT in perimenopausal women, and its subsequent continuation for atheroprevention, new trials will be needed to resolve whether early intervention with estrogen may prevent CVD and/or dementia.

    19. Other primary study, Menopause, 2006, PMID 16607096 Study · partly

      For some cognitive domains, early initiation of HT from around menopause may be beneficial, and initiation of HT in late menopause may be detrimental.

    20. Other primary study, Menopause Int, 2009, PMID 19237622 Study · partly

      It is unclear whether hormone use during the menopausal transition or early postmenopause affects Alzheimer risk.

    21. Trial or observed group, Am J Epidemiol, 2017, PMID 28938710 Study · partly

      When examined according to years since menopause onset (<10 years) rather than age group, results were nonsignificant and concordant for both studies.

    22. Other primary study, Int J Cardiol Heart Vasc, 2019, PMID 30705938 Study · partly

      However, younger HRT initiators remained at an increased risk of stroke, TIA and systemic embolism and this risk increased as average age increased.

    23. Other primary study, Hum Brain Mapp, 2020, PMID 32856754 Study · partly

      In addition, for women using hormonal replacement therapy (HRT), starting treatment earlier was associated with less evident brain aging, but only in women with a genetic risk for AD.

    24. Other primary study, Menopause, 2026, PMID 41632236 Study · partly

      Initiation of HT after age 65 is linked to significantly increased risks of cancer and vascular events, supporting current guidelines discouraging late initiation.

    25. Susan Davis, cited on The Drive, at 2:08:13 Study · negative

      “even the timing hypothesis using Premro which was the medicine used in the WHI is under question.”

Where the sources disagree

Leaning for

HRT gives the most benefit when started near menopause onset, within about 10 years.

Supports it 12 sources
Partly 12 sources

Researchers

Studies

Against it 1 source

Precis is not affiliated with or endorsed by YouTube or by any researcher, show or publisher we quote. We take no sponsorship, ad or affiliate money, and every verdict is our own review of what was said. How we stay independent

Detailed Answer

HRT gives the most benefit when started near menopause onset. This is the "timing hypothesis": hormone therapy started near onset behaves differently from therapy started a decade or more later. The window runs broadly within ~10 years of the final period, at ages roughly 50-59.

That is where the heart, bone and brain benefits concentrate. Estrogen works better early than as a late rescue.

You don't have to wait for periods to stop

Mark Hyman, on his own show, treats hormone therapy as fitting once perimenopausal symptoms begin. He does not wait for the textbook definition of menopause, 12 months without a period. Peter Attia favors the same early-start logic.

Mary Claire Haver, a guest on Andrew Huberman's show, calls it protective when started in that age range. Sara Gottfried, another guest, frames the years soon after menopause as generally safe and helpful.

Where the evidence disagrees

Urologist Rachel Rubin, a guest on Attia's show, pushes against a strict window. She argues recent data challenges strict age cutoffs and that clinicians should offer therapy more widely, mainly for hot flashes, bone protection and genitourinary symptoms.

How long to stay on

The open question sits at the other end: how long to continue. Attia calls long-term use well past the window the field's biggest remaining unknown. That makes starting early firmer ground than staying on indefinitely.

The November 2025 FDA label update echoes the early-start framing, noting benefits when therapy starts within about 10 years of menopause onset.

None of this is a green light to start on your own. The window tells you when the benefit-to-risk math looks best. The decision on candidacy, formulation, route and dose belongs with a menopause-trained clinician who knows your history.

Related Questions

Can you start HRT during perimenopause?
Yes. Starting when perimenopausal symptoms begin, rather than waiting for periods to stop, is on the record, and the timing hypothesis favors starting near onset for the most benefit.
Is it ever too late to start HRT?
The benefits concentrate when therapy starts within ~10 years of menopause onset. Starting much later as a rescue is where caution rises, and long-term use beyond the window is the biggest remaining unknown. Rachel Rubin argues strict age cutoffs are weaker than they look.
What age should you start HRT?
Broadly ages ~50-59, or within ~10 years of menopause onset, the window the FDA's November 2025 label guidance stresses. It tracks symptom onset, not a birthday, and your clinician sets the timing with you.

More Questions About HRT & Menopause

Is HRT safe now? What the FDA change and the ev... Is the estrogen patch safer than pills? (Transd... Is vaginal estrogen safe? What did the WHI study actually show about HRT? Does creatine help with menopause and perimenop...

Precis membership

Get the exact protocol for HRT & Menopause

The answer above is the whole answer: the verdict, every counted mention, where the sources disagree, and the receipt behind each one. Nothing on this page is held back.

A free account adds

  • Each dose named on the record, and the form named with it
  • Timing, and what to take it with or keep it away from
  • The interactions flagged by name

Pro adds

  • Chat answers drawn from 3,700+ hours of recorded interviews with 380 researchers and doctors, plus 48,500+ research studies, each with a timecode
Go Pro — $9/mo or $79/yr

Full HRT & Menopause evidence report

The verdict on every claim, and where the sources disagree

How Precis checks a claim · Report an error

All answers